Everything you need to know about Palantir, the secretive company coming for all your data
By Sara Morrison,
Vox
| 07. 16. 2020
In the earlier days of the Covid-19 pandemic, many of the country’s public health departments, still reliant on fax machines, were woefully unprepared for the massive amounts of data they needed to process. Looking for a tidy private sector solution to a messy government problem, the Department of Health and Human Services (HHS) paid a shadowy Silicon Valley company with ties to the Trump administration to build something new. That company is called Palantir Technologies, and if you don’t know much about it, that’s by design.
Palantir specializes in data-gathering and analysis, most of which it does for government agencies. It has about $1.5 billion in federal government contracts alone, including, recently, with the Space Force and the Navy. Now, as new Covid-19 case numbers break records daily, Palantir is trying to help organize the information with a new platform called HHS Protect, which will be run by another private company called TeleTracking. This partnership has effectively replaced the Centers for Disease Control and Prevention’s (CDC) National Healthcare Safety Network, per the Trump administration’s orders to hospitals...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...